A detailed history of Kennedy Capital Management, Inc. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 419,905 shares of ABUS stock, worth $1.52 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
419,905
Previous 457,578 8.23%
Holding current value
$1.52 Million
Previous $1.41 Million 14.37%
% of portfolio
0.04%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.12 - $4.56 $117,539 - $171,788
-37,673 Reduced 8.23%
419,905 $1.62 Million
Q2 2024

Aug 14, 2024

BUY
$2.52 - $3.63 $53,101 - $76,491
21,072 Added 4.83%
457,578 $1.41 Million
Q1 2024

May 15, 2024

BUY
$2.26 - $2.92 $111,338 - $143,853
49,265 Added 12.72%
436,506 $1.13 Million
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $9,467 - $14,229
-5,602 Reduced 1.43%
387,241 $968,000
Q1 2023

May 15, 2023

BUY
$2.23 - $3.1 $876,039 - $1.22 Million
392,843 New
392,843 $1.19 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $544M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.